EUROPEAN JOURNAL OF GENERAL MEDICINE, cilt.14, sa.1, ss.1-4, 2017 (ESCI)
Introduction: Combination therapy with four drugs (isoniazid, rifampicin, pyrazinamid and ethambutol) is the treatment of choice in tuberculosis but hepatotoxicity due to these drugs is an important medical concern. Therefore identification of patient groups with increased risk for antituberculosis therapy induced hepatotoxicity is crucial.